Tag: HER2 positive breast cancer

Entinostat Doesn’t Overcome Endocrine Resistance in Breast Cancer

The histone deacetylase (HDAC) inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor–positive, HER2-negative, advanced breast cancer in a phase 3 trial....

What’s Hot, Including a Major Chemotherapy Trial

The “hottest” presentation at the upcoming 2020 San Antonio Breast Cancer Symposium (SABCS) comes from RxPONDER (abstract GS3-00), a major randomized clinical trial assessing use...

pCR in HER2+ Breast Cancer Predicts Long-Term Survival

A pathologic complete response (pCR) to targeted therapy in HER2-positive breast cancer portends good long-term outcomes, according to final results of the phase 3 NeoALTTO/BIG...

FDA Approves First New Drug With International Group

The US Food and Drug Administration today approved the oral therapy tucatinib (Tukysa, Seattle Genetics) for the treatment of advanced HER2-positive breast cancer. This is...

COVID-19 Breast Cancer Patient Triage Guidelines (CPBCC)

What your doctor is reading on Medscape.com: APRIL 08, 2020 — The guideline on COVID-19–related triage of patients with breast cancer was released on...